Login / Signup

Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation.

Patrick M GlassmanCarlos H VillaOscar A Marcos-ContrerasElizabeth D HoodLandis R WalshColin Fred GreinederJacob W MyersonTea ShuvaevaLaura PuentesJacob Samuel BrennerDon L SiegelVladimir R Muzykantov
Published in: Bioconjugate chemistry (2022)
Engineering drug delivery systems for prolonged pharmacokinetics (PK) has been an ongoing pursuit for nearly 50 years. The gold standard for PK enhancement is the coating of nanoparticles with polymers, namely polyethylene glycol (PEGylation), which has been applied in several clinically used products. In the present work, we utilize the longest circulating and most abundant component of blood─the erythrocyte─to improve the PK behavior of liposomes. Antibody-mediated coupling of liposomes to erythrocytes was tested in vitro to identify a loading dose that did not adversely impact the carrier cells. Injection of erythrocyte targeting liposomes into mice resulted in a ∼2-fold improvement in the area under the blood concentration versus time profile versus PEGylated liposomes and a redistribution from the plasma into the cellular fraction of blood. These results suggest that in vivo targeting of erythrocytes is a viable strategy to improve liposome PK relative to current, clinically viable strategies.
Keyphrases
  • drug delivery
  • cancer therapy
  • drug release
  • red blood cell
  • induced apoptosis
  • cell cycle arrest
  • cell death
  • cell proliferation
  • ultrasound guided
  • insulin resistance